#MASHAdventCalendar Day 7 🎄 🎅 In the pursuit of effective treatments against #MASH, 2023 has witnessed promising developments of innovative therapeutics. Among the most advanced, are #Resmetirom (THR-beta from Madrigal Pharmaceuticals), #lanifibranor (pan-PPAR agonist from Inventiva Pharma), #obeticholicacid (FXR-agonist from Intercept Pharmaceuticals), and #semaglutide, a GLP-1 Receptor agonist from Novo Nordisk. Our recent poster presented by Cindy Serdjebi at American Association for the Study of Liver Diseases (AASLD) #TLM2023, in collaboration with Gubra (Michael Feigh), showcases results from the diet-induced obese MASH mouse model (#GAN DIO-MASH). It highlights that both lanifibranor and semaglutide significantly reduce steatosis, with lanifibranor also showing a remarkable reduction in fibrosis, including its thickness. Link to the poster : https://lnkd.in/e4x_ntF6
